De Socio, G.V.; Tordi, S.; Altobelli, D.; Gidari, A.; Zoffoli, A.; Francisci, D.
Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV. J. Clin. Med. 2023, 12, 7759.
https://doi.org/10.3390/jcm12247759
AMA Style
De Socio GV, Tordi S, Altobelli D, Gidari A, Zoffoli A, Francisci D.
Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV. Journal of Clinical Medicine. 2023; 12(24):7759.
https://doi.org/10.3390/jcm12247759
Chicago/Turabian Style
De Socio, Giuseppe Vittorio, Sara Tordi, Debora Altobelli, Anna Gidari, Anastasia Zoffoli, and Daniela Francisci.
2023. "Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV" Journal of Clinical Medicine 12, no. 24: 7759.
https://doi.org/10.3390/jcm12247759
APA Style
De Socio, G. V., Tordi, S., Altobelli, D., Gidari, A., Zoffoli, A., & Francisci, D.
(2023). Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV. Journal of Clinical Medicine, 12(24), 7759.
https://doi.org/10.3390/jcm12247759